Table 2 Sepsis events and antibiotherapy characteristics in the ICU during the study period
Sepsis events and antibiotherapy characteristics | Conventional strategy period 2014 n = 738 | Restrictive strategy period 2015 n = 803 | p value |
|---|---|---|---|
No. patients with at least one sepsis event n (%) (community or acquired) | 380 (51.5) | 327 (40.7) | < 0.01 |
Catecholamines administered for sepsis | 179 (24.3) | 163 (20.3) | 0.06 |
No. patients receiving antibiotics n (%) | 427 (57.9) | 376 (46.8) | < 0.01 |
No. of different antibiotics (median ± IQR) | 2 [1–3] | 2 [1–3] | 0.55 |
Duration of antibiotic therapy (days, median ± IQR) | 6 [4–10] | 5 [3–8] | < 0.01 |
Antibiotic-free days until ICU discharge (days, median ± IQR) | 0 [0–6] | 2 [0–7] | 0.03 |
Antibiotics administered n (%) | |||
Amoxicillin | 29 (6.8) | 73 (19.4) | < 0.01 |
Amoxicillin/clavulanic acid | 115 (26.9) | 65 (17.3) | < 0.01 |
Oxacillin | 20 (4.7) | 28 (7.4) | 0.09 |
Piperacillin/tazobactam | 170 (39.8) | 17 (4.5) | < 0.01 |
Cefazolin (C1G) | 1 (0.2) | 13 (3.5) | < 0.01 |
Cefuroxime (C2G) | 1 (0.2) | 72 (19.1) | < 0.01 |
Cefotaxime/ceftriaxone (C3G) | 192 (45.0) | 159 (42.3) | 0.44 |
Cefoxitin (cephamycin) | 9 (2.1) | 34 (9.0) | < 0.01 |
Ceftazidime | 19 (4.4) | 47 (12.5) | < 0.01 |
Cefepime | 7 (1.6) | 18 (4.8) | 0.01 |
Carbapenem | 52 (12.2) | 13 (3.5) | < 0.01 |
Vancomycin | 43 (10.1) | 8 (2.1) | < 0.01 |
Aminoglycoside | 162 (37.9) | 114 (30.3) | 0.02 |
Fluoroquinolone | 13 (3.0) | 45 (12.0) | < 0.01 |
Macrolide | 63 (14.8) | 55 (14.6) | 0.96 |
Clindamycin | 4 (0.9) | 5 (1.3) | 0.74 |
Metronidazole | 17 (4.0) | 19 (5.1) | 0.46 |
Trimethoprim/sulfamethoxazole | 17 (4.0) | 26 (6.9) | 0.06 |
Antibiotics targeting anaerobic pathogens n (%)a | 279 (65.3) | 126 (33.5) | < 0.01 |